首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal VEGFReceptor1 Antibody

  • 中文名: VEGF Receptor 1抗体
  • 别    名: VEGFR-1; VEGF Receptor 1; FLT-1; FLT; FRT; VEGFR1; Fms-like tyrosine kinase 1; Tyrosine-protein kinase FRT
货号: IPDX22755
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 1/500-1/1000 Human,Mouse,Rat
IF 1/20 Human,Mouse,Rat
IHC 1/50-1/100 Human,Mouse,Rat
ICC 1/50-1/200 Human,Mouse,Rat
FCM 1/50-1/100 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesVEGFR-1; VEGF Receptor 1; FLT-1; FLT; FRT; VEGFR1; Fms-like tyrosine kinase 1; Tyrosine-protein kinase FRT
Entrez GeneID2321
WB Predicted band sizeCalculated MW: 151 kDa; Observed MW: 151 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman,Mouse,Rat
ImmunogenA synthesized peptide derived from human VEGF Receptor 1
FormulationPurified antibody in PBS with 0.05% sodium azide.

+ +

参考文献

以下是关于VEGF Receptor 1抗体的3篇参考文献及其摘要概要:

1. **"Anti-VEGFR1 (Flt-1) Therapy: A Novel Approach to Inhibit Tumor Angiogenesis and Metastasis"**

- **作者**: Huang Y. 等 (2003)

- **摘要**: 该研究报道了一种靶向VEGFR1的单克隆抗体在临床前肿瘤模型中的应用,显示其通过阻断VEGF/VEGFR1信号通路显著抑制肿瘤血管生成和转移,提示其在抗肿瘤治疗中的潜力。

2. **"Structural and Functional Characterization of a Monoclonal Antibody to Vascular Endothelial Growth Factor Receptor 1"**

- **作者**: Starovasnik M.A. 等 (2002)

- **摘要**: 文章解析了抗VEGFR1抗体的晶体结构,揭示了其与受体结合的特异性表位,并通过体外实验证明该抗体有效抑制VEGFR1介导的内皮细胞迁移,为抗体优化提供了结构基础。

3. **"Targeting VEGFR1 in Ovarian Cancer: Results from a Phase II Clinical Trial of the Anti-VEGFR1 Antibody IMC-18F1"**

- **作者**: Coleman R.L. 等 (2015)

- **摘要**: 这项II期临床试验评估了IMC-18F1(抗VEGFR1抗体)在复发性卵巢癌患者中的疗效,结果显示其耐受性良好,并观察到部分患者的肿瘤稳定,提示需进一步验证其临床效果。

4. **"VEGFR1 Signaling in Cancer: Insights into Therapeutic Targeting"**

- **作者**: Fischer C. 等 (2008)

- **摘要**: 综述探讨了VEGFR1在肿瘤微环境中的作用,总结了抗VEGFR1抗体的开发进展,强调其在抑制肿瘤相关巨噬细胞活化和转移中的独特机制,为联合治疗提供理论依据。

这些文献涵盖基础研究、结构分析及临床转化,反映了抗VEGFR1抗体的多样化研究路径。

背景信息

Vascular endothelial growth factor receptor 1 (VEGFR1), also known as Flt-1. is a tyrosine kinase receptor primarily involved in angiogenesis and vascular regulation. It binds VEGF-A, VEGF-B, and placental growth factor (PlGF), playing a critical role in embryonic vascular development, pathological angiogenesis, and inflammatory responses. Unlike VEGFR2 (KDR), which drives strong pro-angiogenic signals, VEGFR1 often acts as a decoy receptor to modulate VEGF availability or initiates subtler signaling pathways influencing cell migration, survival, and vascular permeability.

Antibodies targeting VEGFR1 are designed to block ligand-receptor interactions or inhibit downstream signaling, offering therapeutic potential in cancers, age-related macular degeneration, and diabetic retinopathy. In research, these antibodies are widely used to study VEGFR1's expression patterns, ligand-binding dynamics, and functional roles in disease models. They also serve as tools for immunohistochemistry, flow cytometry, and Western blotting to detect receptor localization and activation status.

The development of VEGFR1-specific antibodies has advanced understanding of its dual role—both in promoting pathological angiogenesis (e.g., tumor growth) and in maintaining vascular homeostasis. Clinical trials exploring anti-VEGFR1 therapies aim to disrupt aberrant angiogenesis while minimizing off-target effects, highlighting its importance as a biomarker and therapeutic target in vascular-associated diseases.

客户数据及评论

折叠内容

大包装询价

×